KNSA — Kiniksa Pharmaceuticals International plc price, chart and key statistics

Price data

Price

$83.17

YTD price return

+101.62%

YTD total return

+101.62%

Next earnings

Oct 27, 2026

Market cap

6.5B2018-09 1.3B2026-10 6.5B+414.4% over the window

Enterprise value

6.1B

Shares outstanding

78M2018-06 49.4M2026-06 78M+57.7% over the window

52W low

$35.20

52W high

$83.78

From 52W high

-0.73%

From 52W low

+136.28%

52W range

99%

Volume

Rel volume

2.07×

30D volume

596.4K

30D $ vol

46.4M

Fundamentals

Sales (ttm)

840.8M2021-12 38.5M2026-06 840.8M+2081.5% over the window

Sales/share

$10.782021-12 $0.562026-06 $10.78+1832.0% over the window

EPS (ttm)

$0.982019-12 -$2.992026-06 $0.98-132.9% over the window

FCF (ttm)

182.8M2017-12 -50.3M2026-06 182.8M-463.6% over the window

FCF/share

$2.342017-12 -$1.022026-06 $2.34-330.5% over the window

Book value/share

$8.392017-12 -$1.812026-06 $8.39-562.4% over the window

Net margin

9.59%2021-12 -409.7%2026-06 9.6%-102.3% over the window

ROE

12.33%2018-12 -37.0%2026-06 12.3%-133.4% over the window

ROA

9.00%2017-12 -136.6%2026-06 9.0%-106.6% over the window

Current ratio

3.902017-12 2.702026-06 3.90+44.5% over the window

Growth (CAGR, ttm) · 10Y

Sales

+58.90%2025-06-30 → 2026-06-30529.3M → 840.8M (+58.9% total)+44.12%2023-06-30 → 2026-06-30280.8M → 840.8M (+199.4% total)+98.52%2021-12-31 → 2026-06-3038.5M → 840.8M (+2081.5% total)n/a

Net income

+1587.14%2025-06-30 → 2026-06-304.8M → 80.7M (+1583.9% total)-29.60%2023-06-30 → 2026-06-30231.3M → 80.7M (-65.1% total)n/an/a

FCF

+175.17%2025-06-30 → 2026-06-3066.5M → 182.8M (+175.0% total)+62.72%2023-06-30 → 2026-06-3042.4M → 182.8M (+331.0% total)n/an/a

Shares

+5.34%2025-06-30 → 2026-06-3074M → 78M (+5.3% total)+3.66%2023-06-30 → 2026-06-3070M → 78M (+11.4% total)+2.64%2021-06-30 → 2026-06-3068.5M → 78M (+13.9% total)n/a

Per-share growth (CAGR, ttm) · 10Y

EPS

+1434.96%2025-06-30 → 2026-06-30$0.06 → $0.98 (+1432.1% total)-32.98%2023-06-30 → 2026-06-30$3.27 → $0.98 (-69.9% total)n/an/a

Sales/share

+50.85%2025-06-30 → 2026-06-30$7.15 → $10.78 (+50.8% total)+39.03%2023-06-30 → 2026-06-30$4.01 → $10.78 (+168.8% total)+93.22%2021-12-31 → 2026-06-30$0.56 → $10.78 (+1832.0% total)n/a

FCF/share

+161.23%2025-06-30 → 2026-06-30$0.90 → $2.34 (+161.1% total)+56.98%2023-06-30 → 2026-06-30$0.61 → $2.34 (+286.9% total)n/an/a

Book value/share

+25.48%2025-06-30 → 2026-06-30$6.69 → $8.39 (+25.5% total)+12.57%2023-06-30 → 2026-06-30$5.88 → $8.39 (+42.7% total)+19.49%2021-06-30 → 2026-06-30$3.44 → $8.39 (+143.6% total)n/a

Price

+113.42%2025-10-20 → 2026-10-20$38.99 → $83.17 (+113.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+74.78%2023-10-20 → 2026-10-20$15.57 → $83.17 (+434.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+50.24%2021-10-20 → 2026-10-20$10.87 → $83.17 (+665.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a

Total return

+113.42%2025-10-20 → 2026-10-20$38.99 → $83.17 (+113.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+74.78%2023-10-20 → 2026-10-20$15.57 → $83.17 (+434.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+50.24%2021-10-20 → 2026-10-20$10.87 → $83.17 (+665.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.

84.5×2018-09 -19.442026-10 80.41-513.7% over the window

Fwd P/E

48.6×

P/S (ttm)Market cap ÷ TTM revenue.

7.7×2021-12 21.092026-10 7.71-63.4% over the window

P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.

9.9×2018-09 3.692026-10 9.91+168.8% over the window

P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).

35.5×2018-09 -25.072026-10 35.47-241.5% over the window

EV/EBITDA (fy)

59.6×

EV/Sales (ttm)

7.2×

FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.

2.82%2018-12 -7.0%2026-06 3.7%-152.3% over the window

Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 78.0M ÷ 74.0M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.

-5.34%

Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-5.34%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($2B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.

-5.34%

Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($6.5B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.

0.00%2018-12 0.0%2026-06 0.0%

Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($6.5B). Same caveat as the cash buyback yield.

0.00%2018-12 0.0%2026-06 0.0%

Vs own 10Y history

P/S

85th

P/B

100th

P/FCF

41st